Astrocytes are the most abundant glial cells in the central nervous system, and in the healthy brain they perform a long list of housekeeping duties. They regulate the chemical environment around synapses, supply metabolic support to neurons, recycle neurotransmitters, and help maintain the blood-brain barrier. When injury, stroke, or neurodegenerative disease strikes, however, astrocytes undergo a dramatic transformation. They hypertrophy, proliferate, and secrete extracellular matrix molecules, forming a dense glial scar. This scar has a dual character. On one hand, it limits inflammation and seals off damaged tissue, preventing the injury from spreading. On the other, it secretes chemical signals that suppress axon regrowth and stands in place of the neurons that were lost. For decades, researchers have debated whether the scar is a friend or an enemy of recovery, and a growing body of work has explored whether the cells inside it could be redirected toward a more useful fate.

The idea of converting glial cells into neurons is not new. Direct lineage reprogramming, or transdifferentiation, forces a differentiated cell to switch identities without passing through an embryonic stem-cell-like state. Earlier studies showed that transcription factors such as NeuroD1, Ascl1, and Ngn2 could push astrocytes, and in some cases reactive astrocytes specifically, toward neuronal fates. In vivo conversion experiments, in which the reprogramming factors were delivered directly into injured brains or spinal cords, generated considerable excitement because they suggested a way to regenerate neurons at the site of damage without transplanting cells. Yet the field has also faced skepticism. Some follow-up studies questioned whether the converted cells were truly derived from astrocytes rather than from a small reservoir of neuronal progenitors, and others found that the induced neurons did not always mature into fully functional circuit elements. Building a method that is both efficient at targeting scar-forming astrocytes and reliable at producing working neurons has remained a significant challenge.

TRANsCre-DIONE, as described in the new report, is designed to meet that challenge head-on. The technique combines genetic targeting elements that drive reprogramming specifically in reactive astrocytes with a factor system that pushes the targeted cells toward a motor neuron identity. The reactive astrocyte specificity matters for two reasons. First, it concentrates the reprogramming machinery where it is needed most, in the scar tissue that accumulates after injury. Second, it minimizes off-target conversion of other cell types, including resting astrocytes that are still performing their normal supportive functions and oligodendrocyte lineage cells that maintain the myelin sheaths around axons. Precision of this kind is a recurring concern in gene therapy approaches to the nervous system, where delivery vehicles cannot always discriminate between neighboring cell populations.

According to the study, the converted cells do not merely adopt a superficial neuronal appearance. The authors report that TRANsCre-DIONE-derived cells acquire molecular signatures characteristic of motor neurons, including expression of marker genes associated with that lineage, and display electrophysiological properties consistent with functional neurons, such as the ability to fire action potentials and form synaptic connections. Functional maturation is the gold standard in the reprogramming field because many induced neurons stall at an immature state, resembling embryonic neurons rather than the specialized adult cell types needed to restore lost functions. Motor neurons in particular carry a heavy burden: they are the final common pathway through which the brain and spinal cord command muscles to contract, and their loss underlies devastating conditions ranging from spinal cord injury to amyotrophic lateral sclerosis.

The implications for motor neuron diseases and spinal cord injury are among the most compelling aspects of the work. In amyotrophic lateral sclerosis, the progressive degeneration of motor neurons leaves scar-forming glia in their wake, and any therapy that could recruit those resident glial cells to replace lost neurons would in principle address both the cell loss and the inhibitory environment at the same time. Similarly, after traumatic spinal cord injury, the lesion core becomes dominated by reactive astrocytes, and converting even a fraction of them into neurons capable of relaying motor commands could help bridge the gap that currently prevents functional recovery. The study’s demonstration that scar-forming cells, rather than a separate progenitor population, can be redirected toward a motor neuron fate speaks directly to this therapeutic vision.

At the same time, the authors and the broader field are careful to note the distance between a laboratory demonstration and a clinical therapy. Delivering reprogramming factors to cells inside the human central nervous system remains a formidable engineering problem. Viral vectors, the most common delivery vehicles, have limited cargo capacity and raise safety questions, particularly when the factors being delivered are transcription factors with the potential to alter cell identity in unintended ways. Researchers must also show that converted neurons integrate appropriately into existing circuits, receive the right inputs, and project to the correct targets, all without provoking immune responses or tumor-like overgrowth. Long-term studies will be needed to confirm that TRANsCre-DIONE-derived motor neurons survive, maintain their identity, and remain functional over the months and years that a real therapy would require.

There are also scientific questions that the new work will likely stimulate. How closely do the induced motor neurons match their endogenous counterparts at the level of gene expression, chromatin state, and connectivity? Do the converted cells retain any memory of their astrocyte origin that might affect their long-term behavior? And can the approach be tuned so that the timing and extent of conversion can be controlled in a living organism, allowing clinicians to modulate the treatment as recovery proceeds? Answers to these questions will determine whether TRANsCre-DIONE becomes a platform technology adaptable to multiple contexts of nervous system damage, or a specialized tool for specific experimental settings. The study adds to a growing consensus, however, that the cells of the glial scar should be viewed not only as obstacles to recovery but also as a locally abundant source of raw material for repair.

What makes the report resonant beyond its immediate technical contribution is the broader shift in perspective it represents. For most of the history of neuroscience, adult central nervous system neurons were considered irreplaceable, and glial scarring was treated as an irreversible endpoint of injury. Over the past decade, that pessimism has given way to a more dynamic view of the injured nervous system, one in which resident cells retain latent developmental programs that can, under the right molecular instructions, be reawakened. TRANsCre-DIONE contributes to this shift by showing that the very cells that barricade a lesion can be instructed to become the neurons needed to restore function. As the team and other groups refine the efficiency, safety, and controllability of such conversions, the prospect of rebuilding neural circuits from within the scar tissue itself moves from science fiction closer to experimental reality, offering a measure of hope to patients whose conditions have long been considered untreatable.

Subject of Research: Direct conversion of scar-forming reactive astrocytes into functional motor neurons using the TRANsCre-DIONE transdifferentiation approach

Article Title: TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons

Article References: An, H., Lee, H.-L., Cho, D.-W., Hong, J., Lee, H. Y., Lee, J. M., Choi, S., Hwang, I.-Y., Woo, J., Lee, J., Park, M., Yang, Y.-S., Han, S.-C., Ha, Y., & Lee, C. J. (2026). TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01815-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01815-y

Keywords: reactive astrocytes, motor neurons, transdifferentiation, neuroregeneration, glial scarring, gene therapy, cell fate conversion, neuroscience, spinal cord injury, neurodegenerative disease, cellular reprogramming, Experimental and Molecular Medicine

For much of the twentieth century, mammalian development was viewed primarily as a one-way journey. In the classic image proposed by developmental biologist Conrad Waddington in 1957, a ball rolls down a mountainous landscape, leaving the high plateau of developmental potential and settling into increasingly specialized valleys. Embryonic stem cells could differentiate into restricted lineages, but a mature cell was thought to have largely lost the ability to climb back up the landscape. That model captured the stability of cell identity, but it did not fully describe its potential reversibility. The conceptual breakthrough came in 2006, when Shinya Yamanaka and colleagues reported that four transcription factors could convert mouse fibroblasts into cells with properties resembling embryonic stem cells.

The factors—Oct3/4, Sox2, Klf4, and c-Myc, commonly abbreviated as OSKM—act as molecular regulators of gene expression rather than as structural components of the cell. When introduced into differentiated fibroblasts, they reorganize the gene-regulatory circuitry that maintains the mature state. They also reshape chromatin, the DNA-protein material that determines which genes are accessible for transcription. Over time, genes associated with fibroblast identity are silenced while networks linked to self-renewal and pluripotency become active. The process is inefficient and asynchronous: only a small fraction of treated cells successfully complete the transition, and individual cells may pass through different intermediate states before reaching an induced pluripotent state.

This inefficiency revealed that reprogramming is not a simple molecular reset controlled by four independent switches. Instead, it is a competition between stable cellular programs, epigenetic barriers, metabolic changes, and stochastic events. Some cells fail to activate the core pluripotency network, while others enter incomplete or abnormal states. DNA methylation patterns must be extensively remodeled, enhancer activity must be reorganized, and the cell’s metabolism must shift as it moves from a mature somatic program toward a stem-cell-like condition. These changes helped establish a broader principle: differentiation and reprogramming are opposing movements across a dynamic developmental landscape. Understanding how a cell enters, maintains, or exits pluripotency can therefore illuminate both normal development and the mechanisms used to reverse it.

The underlying idea that differentiated cells retain latent developmental potential was demonstrated decades earlier by John Gurdon. In experiments published in 1962, Gurdon transferred the nucleus of a differentiated tadpole intestinal cell into an enucleated frog egg. The reconstructed embryo could develop into a normal tadpole, showing that the specialized nucleus still contained the genetic information required to build an organism. Nuclear transfer, however, depended on the complex environment of an egg cell. Yamanaka’s work was transformative because it showed that mammalian cell identity could be altered using a small set of defined transcription factors alone. The discovery converted a question once associated with embryology into a practical technology that could be reproduced in laboratories around the world.

The next year, researchers generated induced pluripotent stem cells from adult human fibroblasts. Human iPSCs gave scientists a way to create genetically relevant, patient-specific cell lines without relying on embryos. In principle, a skin or blood sample can be reprogrammed and then differentiated into neurons, heart muscle cells, liver cells, retinal cells, or other specialized populations. These cells can carry disease-associated genetic variants, allowing researchers to study pathological mechanisms in a dish. They can also be used to test candidate medicines on human-derived tissue, potentially revealing toxicities or treatment responses that conventional animal models do not predict reliably. Yet the technology carries important technical challenges, including genomic instability, residual epigenetic memory, variation between cell lines, incomplete differentiation, and the risk that undifferentiated cells could form tumors after transplantation.

The clinical ambitions of the field are now moving beyond theory. Early-stage trials have tested cell products derived from pluripotent stem cells, including retinal pigment epithelium intended to treat macular degeneration and dopaminergic neurons designed to replace cells lost in Parkinson’s disease. The goal is not simply to place stem cells into damaged tissue, but to manufacture a highly characterized population with the correct identity, maturity, function, and safety profile. Researchers must establish that the cells do not contain dangerous mutations, that unwanted cell types have been removed, and that the transplanted population behaves predictably over time. Manufacturing at clinical scale also requires tightly controlled culture conditions, standardized quality testing, and long-term monitoring of patients.

The field is simultaneously expanding in directions that challenge the original definition of reprogramming. Partial reprogramming, for example, exposes cells to reprogramming factors for a limited period rather than pushing them all the way to pluripotency. In experimental systems, this approach has been used to reverse some molecular features associated with aging while preserving aspects of the cell’s original identity. The strategy is technically delicate: too little reprogramming may produce minimal benefit, while too much can erase cell identity or promote abnormal growth. Chemical reprogramming offers another alternative. Instead of delivering transcription-factor genes, researchers use combinations of small molecules to alter signaling pathways, chromatin states, metabolism, and transcriptional regulation. This may improve control over timing and reduce some risks associated with genetic delivery, although efficiency, reproducibility, and safety remain major obstacles.

New measurement technologies are making these transitions visible at unprecedented resolution. Single-cell RNA sequencing can track gene-expression changes in individual cells rather than averaging signals across an entire culture. Single-cell epigenomic methods reveal how DNA methylation, histone modifications, and chromatin accessibility change during fate conversion. Spatial transcriptomics adds a geographic dimension, showing where distinct cell states occur within tissues or organoid structures. Advanced imaging can follow cell division, morphology, and lineage behavior in real time, while computational models reconstruct gene-regulatory networks and identify the molecular events that separate successful reprogramming from failure. Together, these approaches are transforming cellular identity from a static label into a measurable trajectory through molecular and physical states.

Another rapidly developing frontier is the construction of stem-cell-based embryo and tissue models. Organoids can reproduce selected features of organs, including aspects of tissue architecture, physiology, and disease. More integrated models attempt to recreate interactions among multiple lineages during early development, offering a way to investigate processes that are difficult or impossible to observe directly in embryos. These systems can reveal how signaling pathways, mechanical forces, cell migration, chromatin organization, and metabolism cooperate to produce organized tissues. They also raise difficult ethical and regulatory questions, particularly as models become more complex and begin to resemble aspects of embryonic development more closely. The anniversary collection announced by BMC Biology is intended to bring together research addressing these biological, technological, and ethical challenges.

Twenty years after OSKM first overturned the idea that development is irreversible, the central question has become more precise: not merely whether a cell can change identity, but how that change is initiated, stabilized, coordinated across a population, and safely directed toward a therapeutic outcome. Scientists are now examining developmental plasticity in diverse species, the spatial organization of lineage decisions, the molecular logic of tissue patterning, and the systems-level principles that integrate gene regulation with signaling, metabolism, and mechanics. The history of iPSCs began with a compact set of transcription factors, but its future will depend on far more than four genes. It will require predictive models of cell fate, reliable methods for producing mature functional cells, and rigorous safeguards that convert cellular plasticity into medicine without sacrificing biological control.

Subject of Research: Induced pluripotent stem cells, cellular reprogramming, pluripotency, differentiation, developmental plasticity, stem-cell-based models, and regenerative medicine

Article Title: Pluripotency, differentiation, and reprogramming: 20 years of induced pluripotent stem cells

Article References: Takahashi and Yamanaka, Cell (2006), DOI: 10.1016/j.cell.2006.07.024; Gurdon, Journal of Embryology and Experimental Morphology (1962); Takahashi et al., Cell (2007), DOI: 10.1016/j.cell.2007.11.019; Yu et al., Science (2007), DOI: 10.1126/science.1151526; Shi et al., Nature Reviews Drug Discovery (2017), DOI: 10.1038/nrd.2016.245; Mandai et al., New England Journal of Medicine (2017), DOI: 10.1056/NEJMoa1608368; Sawamoto et al., Nature (2025), DOI: 10.1038/s41586-025-08700-0; Ocampo et al., Cell (2016), DOI: 10.1016/j.cell.2016.11.052; Guan et al., Nature (2022), DOI: 10.1038/s41586-022-04593-5; Eiraku et al., Nature (2011), DOI: 10.1038/nature09941

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02712-6

Keywords: induced pluripotent stem cells, iPSCs, pluripotency, cellular reprogramming, OSKM, Yamanaka factors, differentiation, stem cell biology, regenerative medicine, organoids, embryo models, single-cell multi-omics, spatial transcriptomics, partial reprogramming, chemical reprogramming